ABACAVIR SULFATE AND LAMIVUDINE Drug Patent Profile

« Back to Dashboard

Which patents cover Abacavir Sulfate And Lamivudine, and when can generic versions of Abacavir Sulfate And Lamivudine launch?

Abacavir Sulfate And Lamivudine is a drug marketed by Pharmobedient, Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Hetero Labs Ltd V, Laurus, Macleods Pharms, Teva Pharms Usa, and Zydus Pharms. and is included in ten NDAs.

The generic ingredient in ABACAVIR SULFATE AND LAMIVUDINE is abacavir sulfate; lamivudine. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abacavir Sulfate And Lamivudine

A generic version of ABACAVIR SULFATE AND LAMIVUDINE was approved as abacavir sulfate; lamivudine by CHARTWELL RX on March 28^th, 2017.

Summary for ABACAVIR SULFATE AND LAMIVUDINE

US Patents:	0
Applicants:	10
NDAs:	10
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	8
Patent Applications:	1,005
DailyMed Link:	ABACAVIR SULFATE AND LAMIVUDINE at DailyMed

Recent Clinical Trials for ABACAVIR SULFATE AND LAMIVUDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ViiV Healthcare	Phase 4
Gilead Sciences	Phase 3
GlaxoSmithKline	Phase 4

See all ABACAVIR SULFATE AND LAMIVUDINE clinical trials

Pharmacology for ABACAVIR SULFATE AND LAMIVUDINE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Cytochrome P450 1A1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors

US Patents and Regulatory Information for ABACAVIR SULFATE AND LAMIVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	ABACAVIR SULFATE AND LAMIVUDINE	abacavir sulfate; lamivudine	TABLET, FOR SUSPENSION;ORAL	204311-001	Dec 22, 2023		DISCN	Yes	No
Laurus	ABACAVIR SULFATE AND LAMIVUDINE	abacavir sulfate; lamivudine	TABLET;ORAL	216332-001	Jul 25, 2022	AB	RX	No	No
Chartwell Rx	ABACAVIR SULFATE AND LAMIVUDINE	abacavir sulfate; lamivudine	TABLET;ORAL	204990-001	Mar 28, 2017	AB	RX	No	No

Abacavir Sulfate and Lamivudine Market Dynamics, Patent Status, and Financial Trajectory

Last updated: October 7, 2026

Abacavir sulfate/lamivudine is a mature fixed-dose antiretroviral combination marketed originally as Epzicom in the United States and Kivexa in Europe. The product has lost primary market exclusivity, faces generic competition, and has been displaced clinically by newer dolutegravir- and tenofovir-based regimens. Its remaining commercial value is concentrated in generic volume, treatment-experienced patients, selected patients with renal constraints, and the broader abacavir-based Triumeq franchise.

What is abacavir sulfate and lamivudine?

Abacavir sulfate/lamivudine combines two nucleoside reverse transcriptase inhibitors:

Product	Active ingredients	Original sponsor	Primary use	Regulatory status
Epzicom	Abacavir sulfate 600 mg plus lamivudine 300 mg	GlaxoSmithKline	HIV-1 treatment with other antiretrovirals	FDA approved
Kivexa	Abacavir 600 mg plus lamivudine 300 mg	ViiV Healthcare/GSK	HIV-1 treatment with other antiretrovirals	Authorized in multiple non-U.S. markets
Ziagen	Abacavir sulfate	GlaxoSmithKline/ViiV	HIV-1 treatment	FDA approved
Epivir	Lamivudine	GlaxoSmithKline	HIV-1 and chronic hepatitis B, depending on formulation	FDA approved
Triumeq	Abacavir, dolutegravir, and lamivudine	ViiV Healthcare	Complete HIV-1 regimen	FDA approved

Abacavir inhibits HIV reverse transcriptase after intracellular conversion to its active carbovir triphosphate form. Lamivudine is converted to lamivudine triphosphate and inhibits viral DNA synthesis. The combination does not provide a complete regimen by itself and is used with other antiretroviral agents. [1,2]

Abacavir requires pharmacogenetic screening for the HLA-B*57:01 allele because carriers face a materially higher risk of hypersensitivity reactions. Current U.S. labeling recommends testing before initiation, and patients with a positive result should not receive abacavir-containing products. [1]

When did abacavir/lamivudine lose exclusivity?

U.S. market exclusivity for the individual active ingredients expired long before the fixed-dose combination became a mature generic product.

Milestone	Approximate date	Commercial implication
Epivir approval	1995	Lamivudine entered the U.S. HIV market
Ziagen approval	1998	Abacavir entered the U.S. HIV market
Epzicom approval	August 2004	Fixed-dose abacavir/lamivudine launched
New chemical-entity exclusivity for abacavir/lamivudine	Expired in 2009	FDA statutory exclusivity ended
Core branded patent period	Expired during the 2010s	Generic entry became commercially feasible
Generic abacavir/lamivudine approvals	Began during the 2010s	Price competition expanded
Current market	Mature generic market	Brand demand is concentrated in limited segments

The exact commercial transition differed by jurisdiction because patent expiry, pediatric exclusivity, regulatory approval timing, and local reimbursement rules were not identical. In the United States, the product is no longer protected by a meaningful period of new-drug exclusivity. FDA Orange Book records are the controlling source for currently listed patents and exclusivity data. [3]

What patents protect abacavir sulfate and lamivudine?

The original patent estate covered the active compounds, pharmaceutical compositions, treatment methods, and specific combinations. Most commercially important protection has expired.

Active-ingredient patents

The original abacavir and lamivudine compound patents created the early market barriers. Those patents are no longer effective barriers to ordinary generic tablets in the United States and major European markets.

Fixed-dose combination patents

The abacavir/lamivudine combination was protected by patents directed to:

• The combination of the two nucleoside analogues.
• Pharmaceutical compositions containing specified ratios or dosage strengths.
• Methods for treating HIV infection.
• Tablet formulations and manufacturing processes.
• Pediatric or reduced-dose presentations in selected jurisdictions.

These patents supported the branded Epzicom and Kivexa franchises but do not create a current broad barrier to standard generic 600 mg/300 mg tablets.

Method-of-use patents

Method-of-use protection historically covered HIV treatment with abacavir, lamivudine, or both. Such patents had limited long-term value because generic manufacturers could seek approval using non-infringing labeling, where permitted, or rely on the expiration of the relevant use claims.

Triumeq-related protection

The economically more important surviving abacavir/lamivudine patent exposure historically related to Triumeq, which adds dolutegravir. That estate is separate from the basic Epzicom combination and has had greater commercial importance because Triumeq was sold as a complete single-tablet regimen.

Triumeq’s commercial protection has included patents directed to:

• Dolutegravir compounds.
• Dolutegravir salt and crystalline forms.
• Combinations containing dolutegravir, abacavir, and lamivudine.
• Pharmaceutical compositions and tablet formulations.
• Pediatric formulations and specific dosing approaches.

The legal position for Triumeq must be assessed separately from the generic availability of abacavir/lamivudine. A generic Epzicom substitute does not automatically provide a substitute for Triumeq because it lacks dolutegravir.

What is the Orange Book status of abacavir/lamivudine?

The FDA Orange Book identifies approved products, therapeutic equivalence information, patents, and exclusivity. Abacavir sulfate/lamivudine is a legacy small-molecule combination rather than a biologic, so biosimilar rules do not apply. [3]

The market has three distinct regulatory categories:

1. Brand Epzicom: The original fixed-dose combination.
2. Authorized or branded-generic versions: Products supplied under licensing, distribution, or alternative labeling arrangements.
3. ANDA generics: Abbreviated New Drug Application products demonstrating bioequivalence to the reference product.

Generic applicants can generally rely on the reference product’s safety and efficacy findings and must establish pharmaceutical equivalence and bioequivalence. Because the active ingredients are well characterized and the product is an immediate-release tablet, the regulatory barrier is materially lower than for long-acting injectables, inhaled products, complex formulations, or biologics.

How many patents currently cover abacavir/lamivudine?

No broad, commercially decisive U.S. patent barrier remains for ordinary abacavir sulfate/lamivudine tablets. Historical patent families covered the active ingredients and combination, but their principal terms have expired.

The relevant distinction is between:

Question	Market assessment
Are the active ingredients patent-protected in the United States?	No meaningful composition-of-matter barrier remains
Is the basic fixed-dose combination broadly blocked?	No
Are selected formulations or methods potentially protected in some markets?	Possible, but limited commercial effect
Does Triumeq have separate patent exposure?	Yes, historically more significant
Is the product a biologic subject to biosimilar exclusivity?	No
Can generic entry occur through an ANDA?	Yes, subject to FDA requirements and applicable certifications

Patent numbers and status vary by product, jurisdiction, and formulation. The relevant current records are the FDA Orange Book, FDA product-specific guidances, USPTO records, and national patent registers. [3-5]

Which companies are challenging the branded product?

The principal competitive threat has come from generic pharmaceutical manufacturers rather than biosimilar developers. Companies that have historically participated in generic antiretroviral markets include:

• Teva Pharmaceuticals
• Mylan, now part of Viatris
• Aurobindo Pharma
• Cipla
• Hetero
• Sun Pharmaceutical Industries
• Lupin
• Dr. Reddy’s Laboratories
• Laurus Labs and associated supply partners

The competitive field varies by country. In the United States, generic participation depends on ANDA approvals, commercial launch decisions, supply economics, and contracting. In low- and middle-income countries, procurement agencies and voluntary licensing arrangements have had a larger effect on price and supplier concentration.

What Paragraph IV challenges affected abacavir/lamivudine?

Paragraph IV litigation was more relevant during the transition from branded exclusivity to generic availability. An ANDA applicant may certify that a listed patent is invalid, unenforceable, or not infringed. A patent-holder suit within the statutory period can trigger a regulatory stay, subject to the applicable rules and timing.

For mature abacavir/lamivudine products, the commercial importance of any historical Paragraph IV dispute has declined because:

• The principal composition and combination patents have expired.
• Multiple generic manufacturers can compete after the relevant barriers lapse.
• Litigation damages are constrained by low generic prices and limited remaining patent life.
• The product is not a high-growth branded asset.

There is no current biosimilar litigation pathway because abacavir/lamivudine is a synthetic small-molecule drug.

What formulations are protected by abacavir/lamivudine patents?

The commercially relevant formulation is an immediate-release film-coated tablet containing 600 mg of abacavir and 300 mg of lamivudine. The formulation is relatively simple compared with extended-release, depot, liposomal, inhaled, or biologic products.

Historical formulation claims could cover:

• Tablet excipient combinations.
• Particle size or processing parameters.
• Specific salt forms.
• Film coatings.
• Manufacturing processes.
• Pediatric dosage forms.
• Multidrug tablets containing dolutegravir.

These claims generally have lower strategic value than composition-of-matter claims. A generic manufacturer can often design around a narrow excipient or process claim while preserving the same active ingredients and strength.

How does abacavir/lamivudine compare with competing HIV regimens?

Abacavir/lamivudine has lost share to regimens with stronger guideline positioning, higher resistance barriers, better tolerability profiles, and lower cardiovascular or hypersensitivity concerns.

Regimen	Main commercial advantage	Main limitation
Abacavir/lamivudine plus third agent	Established, once-daily nucleoside backbone; avoids tenofovir renal and bone exposure	HLA-B*57:01 screening; cardiovascular-risk concern; weaker contemporary preference
Dolutegravir/lamivudine	Two-drug regimen with high efficacy and simple dosing	Not suitable for all patients, including certain resistance or hepatitis B scenarios
Bictegravir/emtricitabine/tenofovir alafenamide	Strong efficacy and broad guideline use	Tenofovir-related considerations; branded competition
Dolutegravir plus tenofovir/lamivudine	Widely adopted first-line architecture	Requires tenofovir exposure
Long-acting cabotegravir/rilpivirine	Reduced daily pill burden	Injection logistics, resistance management, and higher administration complexity

U.S. HIV treatment guidelines generally prioritize integrase strand transfer inhibitor-based regimens. Abacavir-containing regimens remain clinically relevant but are no longer the default choice for most treatment-naive patients. [6]

What is the financial trajectory for abacavir sulfate and lamivudine?

The product’s financial trajectory is mature-to-declining in branded markets.

Revenue profile

ViiV Healthcare and its parent companies have historically reported selected product sales, but the market value of abacavir/lamivudine alone is difficult to isolate because financial reporting may combine:

• Epzicom/Kivexa
• Ziagen
• Triumeq
• Other legacy antiretroviral products
• Geographic and exchange-rate effects

The fixed-dose combination has no current growth catalyst comparable with long-acting cabotegravir or newer two-drug regimens. Revenue pressure comes from generic price erosion, therapeutic substitution, and declining use of abacavir as an initial-treatment backbone.

Commercial trajectory

Period	Financial condition	Main driver
2004-2010	Growth and premium branded pricing	Fixed-dose convenience and broad HIV use
2011-2016	Early erosion	Patent expiry and generic preparation
2017-2021	Declining standalone value	Generic competition and migration to integrase-based regimens
2022-2025	Mature low-growth or declining product	Generic substitution and reduced clinical preference
Longer term	Residual value	Established supply, treatment-experienced use, and procurement demand

The broader abacavir franchise has retained more value through Triumeq than through Epzicom because Triumeq is a complete single-tablet regimen. That advantage narrows as dolutegravir/lamivudine and newer integrase-based products expand.

Revenue exposure

The highest exposure is concentrated in:

• ViiV and GSK legacy HIV revenue.
• Generic manufacturers with efficient active pharmaceutical ingredient access.
• Public-sector procurement programs.
• Wholesalers and specialty distributors carrying legacy antiretroviral products.
• Health systems where formulary substitution favors low-cost generic tablets.

The lowest exposure is in companies whose HIV portfolios are centered on long-acting injectables, newer integrase inhibitors, or tenofovir-based fixed-dose combinations.

What licensing deals affect abacavir/lamivudine?

Licensing has been important in global access to antiretroviral drugs. The Medicines Patent Pool and originator companies have used voluntary licensing and access arrangements for selected HIV medicines, particularly where patents remain relevant and lower-income-country supply is a priority. [7]

For abacavir/lamivudine, the commercial importance of licensing is lower than during the active patent period because the core ingredients and combination are mature. Licensing can still influence:

• Which suppliers may sell into specific territories.
• Public-sector procurement eligibility.
• Technology transfer.
• Local manufacturing.
• Registration rights.
• Combination products containing abacavir, lamivudine, and dolutegravir.

Territorial rights remain important in countries with different patent terms, regulatory standards, or procurement rules.

What generic launch risks exist?

Generic entry is legally feasible but commercial launch remains subject to practical risks.

Regulatory risks

• Bioequivalence failure.
• Incomplete labeling or HLA-B*57:01 warnings.
• Manufacturing inspection findings.
• Supply interruptions involving active pharmaceutical ingredients.
• Country-specific registration requirements.

Commercial risks

• Low net pricing after tender competition.
• Limited market size in developed countries.
• Entrenched preferred regimens.
• Inventory write-downs after rapid price declines.
• Difficulty obtaining formulary placement.

Manufacturing and IP risks

Abacavir and lamivudine are established synthetic molecules with multiple global suppliers. Manufacturing barriers are therefore moderate to low. The main operational constraints are validated chemistry, impurity control, tablet consistency, regulatory compliance, and reliable supply rather than difficult delivery technology.

A manufacturer pursuing a Triumeq substitute faces a more complex challenge because it must address dolutegravir-related patents, formulation requirements, regulatory strategy, and potentially more valuable branded protection.

What is the competitive landscape for abacavir/lamivudine?

The market is divided between low-cost generic tablets and higher-value combination regimens.

Originator position

ViiV retains the strongest legacy position because it developed and commercialized abacavir-based products and owns substantial HIV commercial infrastructure. Its strategic emphasis has shifted toward:

• Cabotegravir long-acting injections.
• Dolutegravir/lamivudine products.
• Pediatric and global-access formulations.
• Complete regimens rather than individual nucleoside backbones.

Generic position

Generic manufacturers compete primarily on:

• Acquisition cost.
• Tender eligibility.
• Regulatory registrations.
• Supply reliability.
• Geographic reach.
• Government procurement relationships.

The product is unlikely to support durable premium pricing unless a supplier has a protected territory, a supply agreement, or a differentiated distribution channel.

How strong is the patent estate for abacavir/lamivudine?

The patent estate is weak for the basic combination and stronger only when evaluated through related products.

Patent category	Current strength
Abacavir composition patents	Expired
Lamivudine composition patents	Expired
Basic abacavir/lamivudine combination	Expired or commercially nonblocking
Immediate-release tablet	Low barrier
Narrow formulation claims	Limited, design-around potential
Method-of-use claims	Limited value after generic labeling and expiry
Triumeq combination	Historically stronger and product-specific
Long-acting cabotegravir	Strategically stronger than abacavir/lamivudine

The product’s current moat is operational and clinical familiarity rather than patent exclusivity.

What is the FDA regulatory status?

FDA approved Epzicom in 2004 for use with other antiretroviral agents in adults and adolescents above the applicable weight threshold. The product carries warnings for abacavir hypersensitivity, lactic acidosis and severe hepatomegaly with steatosis as a class-related risk, and potential cardiovascular concerns associated with abacavir exposure. [1]

The FDA regulatory pathway for a generic version is an ANDA. No biosimilar application is relevant. The product’s mature regulatory profile supports generic approval, but labeling must preserve clinically important abacavir warnings and contraindications.

What is the likely generic launch scenario?

The most probable scenario is continued multi-supplier generic availability with gradual price compression.

Scenario	Probability assessment	Market effect
Continued generic supply	High	Low prices and limited brand recovery
Single-supplier shortage	Possible	Temporary price increases and procurement disruption
Major branded revival of Epzicom	Low	Clinical preference and generic competition limit upside
Increased use through Triumeq	Limited	Depends on Triumeq positioning and competing integrase regimens
Rapid displacement by long-acting therapy	Gradual	Applies mainly to selected patient segments
New patent-based exclusivity for basic combination	Very low	Core patent estate is mature

Key Takeaways

• Abacavir sulfate/lamivudine is a mature fixed-dose HIV combination with expired core exclusivity.
• Epzicom and Kivexa have been commercially displaced by generics and newer integrase-based regimens.
• The product is a small-molecule drug, so biosimilar competition does not apply.
• The basic combination has no meaningful broad U.S. patent barrier remaining.
• Triumeq has a separate and historically stronger patent and commercial position because it contains dolutegravir.
• Standalone abacavir/lamivudine revenue is generally low-growth or declining and is not a major branded expansion opportunity.
• Generic profitability depends on procurement scale, supply reliability, and manufacturing efficiency.
• The principal remaining value lies in low-cost access markets, treatment-experienced patients, and legacy HIV supply channels.

FAQs

Is abacavir/lamivudine still a preferred first-line HIV treatment?

Usually not. Integrase inhibitor-based regimens, including bictegravir- and dolutegravir-based combinations, generally have stronger contemporary guideline positioning. Abacavir/lamivudine remains useful for selected patients.

Does abacavir/lamivudine require genetic testing?

Yes. HLA-B*57:01 testing is required before starting abacavir-containing treatment in the United States because carriers face a high risk of hypersensitivity reactions.

Can a generic manufacturer sell abacavir/lamivudine without developing a new clinical trial program?

Generally yes. An ANDA applicant can rely on the reference product’s safety and efficacy findings by demonstrating pharmaceutical equivalence and bioequivalence.

Is Triumeq interchangeable with abacavir/lamivudine?

No. Triumeq contains dolutegravir in addition to abacavir and lamivudine. Abacavir/lamivudine alone does not provide the same complete regimen.

Does lamivudine’s hepatitis B use increase the value of the combination?

Not materially for the HIV fixed-dose product. Lamivudine has hepatitis B activity, but the commercial and clinical management of hepatitis B differs from HIV treatment, and resistance limits lamivudine’s role as long-term monotherapy for hepatitis B.

References

1. U.S. Food and Drug Administration. (2023). Epzicom (abacavir sulfate and lamivudine) prescribing information.
2. National Institutes of Health. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. ClinicalInfo.HIV.gov.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Patent and Trademark Office. (2024). Patent Center.
5. U.S. Food and Drug Administration. (2024). Approved drug product list and patent information resources.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). What to start: Initial combination antiretroviral regimens. U.S. Department of Health and Human Services.
7. Medicines Patent Pool. (2024). HIV medicines and licensing agreements.